Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 Return on Equity

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 (HROWM) currently reports a ROE of -244.91%. That is below the Healthcare sector average of 13.26%. Use the charts on this page to explore Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's ROE history and peer comparisons.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's ROE of -244.91% is lower than the Healthcare sector average of 13.26%. That is roughly 1946.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Harrow- 11.875% NT REDEEM 31/12/2027 USD 25's current -244.91% should be judged against Healthcare norms (sector average: 13.26%) and against HROWM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -244.91%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.26%. From there, open related valuation or income-statement pages for Harrow- 11.875% NT REDEEM 31/12/2027 USD 25, and consider following HROWM for alerts when major investors trade the stock.

Harrow- 11.875% NT REDEEM 31/12/2027 USD 25 is classified in the Healthcare sector. On ROE, it currently shows -244.91% versus a sector average near 13.26%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HROWM with unrelated industries.